Company has secured globally exclusive manufacturing rights related to an entire, new, and fully market launched oncology "drug" class called Cellular Intravascular Targeting Agents, CITA. Company's lead product, CITA Cell Pak™
treats in eligible advanced patients many kinds of cancer and all four stages with objective
clinical success and virtually no side effects in routine applications. Company will manufacture CITA Cell Pak™ for various national distributors within the AmeReGen BioPharmaceuticals SPC Consortium of leading (stem) cell companies with products distributorships that are either already post-market-launch and profitable, or that are in the process of new national/territorial market launch and getting set up for strategic partnerings with leading medical centres that can fully appreciate exclusive offerings of our quasi-robotic mass-manufacturing of scale with the highest standardized QA/AC product definitions in the industry.
CITA PURGE Transplants are technology-related to adult (ethical, hematopoietic) stem cell transplantation. As newest, 5th generation of "hematpoietic, autologous stem cell transplant procedures" they no longer require patients to undergo chemo- or radiation treatments, no organ donors or organ matching is required, and CITA are beyond clinical trials for almost a decade, and approved and launched in the FRG within the EU since 2004.
A few facts about CITA: The CITA technology has been developed over 20 years at elite and stem cell hot-bed Stanford University, of Palo Alto, California, USA, and further in the Californian cell therapeutics industry of Silicon Valley/BioBay. Together with Asian top R&D this breakthrough has cumulatively received more than US$250,000,000 in R&D funding, and was found consistently to perform across a broad spectrum of otherwise multi-drug-resistant and lethal cancers. The global demand for innovations that can perform powerfully in such therapy resistant cancers is vast and un-met. In GC Arabia's oncology market of $100+Bln, there is not one domestic liver cancer program that combines liver transplant and stem cell capabilities for the treatment of HCC primary liver cancer, the latter being the fifth most common and #1 most deadly cancer of the entire region.
More than 95% of patients diagnosed with this disease will die from it, less than 10% qualify for liver transplant, and less than 1% can actually get such a potentially life-saving liver transplant due to liver organ shortages. Successful state-of-the-art treatment of liver cancer in the US and EU costs between $1Mln and 2.5Mln including travel, with more than 90% of such costs spent wasted due to the patient dying waiting for a transplantation that never happens - only 10% of liver transplant-waiting patients will ever get an organ...
CITA never have organ shortage: The patient donates his or her own adult stem cells and within a brief 2 weeks (transplant wait listing >1-year) the patient gets a CITA-PURGE™ transplant that will destroy liver cancer from within the tumors, and allows the liver to heal itself thereafter. No chemotherapy, no radiation therapy, and no suffering from major surgery or cancer pains are necessary for the patients to endure any more: This new and already Germany approved cutting edge therapy started to save lives of the Saudi elite as early as 2004, and is now available to the one and best medical center of the region. AmeReGen-GC Arabia is currently searching for the strongest and most excellent medical center of Arabia to build "the Ferrari amongst the liver centers" and make its cutting-edge, robotic produced, premium stem cell products available for technology transfer and import.
The executive team leader and Chairman of the AmeReGen Consortium of Companies is Dr. Ernest G Hope MD PhD (Max-Planck Institute and Stanford University '99) -globally recognized as the Father of Adult Stem Cells since he wrote the world's first publication introducing the then unthinkable concept of "re-enbryonalization of adult differentiated cells" in 1988 at the "Max-Planck Institute -Wunderkind"- age of 22. Today, another 22 years later and his team and he are still pursuing his dream of bringing the first powerful and German reliable, yet entirely side-effect-free cancer cure to the world: The rigorous R&D that started at Stanford Stem Cell Research Laboratories where he obtained both his MD and a PhD in immunology on bone marrow transplant and stem cell research, soon became rational bio-pharmaceutical drug development, added instrumental German engineering and robotics/bio-processes to perfection, and today offers the the best adult stem cells for cancer on the globe. What was an exquisite and famously powerful, yet gentle VIP cancer-rescue program in collaboration with the Park Hyatt Hamburg SPA Hotel is now turn-key available to the most innovative Arab medical center in 2011.
More than 10,000 liver cancer patients -many from the finest families of Arabia- still die each year in the kingdom of Saudi Arabia, alone; there are more than 200,000 cases in the larger region, if one includes neighboring Egypt. Rather than spending an estimated $5-12billion per year on treatments abroad in the US or EU, the single top Arab CITA-PURGE™ transplant centre that AmeReGen GC Arabia will exclusively enable as licensed JV, top stem cell centre of excellence, and long-term partner for clinical liver cancer care, research, and scientific flagship-program of the world (and ahead of the entire US!) - this centre will be able to save up to 14,000 lives of domestic, expatriate, and regional health tourism a year, and not only likely save 3/4 of the multi- $billion re-current expense to each GC Arabian nation to send their premium liver cancer patients abroad, but create a solid Arab domestic $5-10billion+/year liver cancer health care industry fueled by the critical supply of CITA-PAK therapies. Last not least saving 14,000 lives previously lost to liver cancer will be a priceless Sharia accomplishment and the marvel of the region's medical infrastructure.
A few facts about CITA: The CITA technology has been developed over 20 years at elite and stem cell hot-bed Stanford University, of Palo Alto, California, USA, and further in the Californian cell therapeutics industry of Silicon Valley/BioBay. Together with Asian top R&D this breakthrough has cumulatively received more than US$250,000,000 in R&D funding, and was found consistently to perform across a broad spectrum of otherwise multi-drug-resistant and lethal cancers. The global demand for innovations that can perform powerfully in such therapy resistant cancers is vast and un-met. In GC Arabia's oncology market of $100+Bln, there is not one domestic liver cancer program that combines liver transplant and stem cell capabilities for the treatment of HCC primary liver cancer, the latter being the fifth most common and #1 most deadly cancer of the entire region.
More than 95% of patients diagnosed with this disease will die from it, less than 10% qualify for liver transplant, and less than 1% can actually get such a potentially life-saving liver transplant due to liver organ shortages. Successful state-of-the-art treatment of liver cancer in the US and EU costs between $1Mln and 2.5Mln including travel, with more than 90% of such costs spent wasted due to the patient dying waiting for a transplantation that never happens - only 10% of liver transplant-waiting patients will ever get an organ...
CITA never have organ shortage: The patient donates his or her own adult stem cells and within a brief 2 weeks (transplant wait listing >1-year) the patient gets a CITA-PURGE™ transplant that will destroy liver cancer from within the tumors, and allows the liver to heal itself thereafter. No chemotherapy, no radiation therapy, and no suffering from major surgery or cancer pains are necessary for the patients to endure any more: This new and already Germany approved cutting edge therapy started to save lives of the Saudi elite as early as 2004, and is now available to the one and best medical center of the region. AmeReGen-GC Arabia is currently searching for the strongest and most excellent medical center of Arabia to build "the Ferrari amongst the liver centers" and make its cutting-edge, robotic produced, premium stem cell products available for technology transfer and import.
The executive team leader and Chairman of the AmeReGen Consortium of Companies is Dr. Ernest G Hope MD PhD (Max-Planck Institute and Stanford University '99) -globally recognized as the Father of Adult Stem Cells since he wrote the world's first publication introducing the then unthinkable concept of "re-enbryonalization of adult differentiated cells" in 1988 at the "Max-Planck Institute -Wunderkind"- age of 22. Today, another 22 years later and his team and he are still pursuing his dream of bringing the first powerful and German reliable, yet entirely side-effect-free cancer cure to the world: The rigorous R&D that started at Stanford Stem Cell Research Laboratories where he obtained both his MD and a PhD in immunology on bone marrow transplant and stem cell research, soon became rational bio-pharmaceutical drug development, added instrumental German engineering and robotics/bio-processes to perfection, and today offers the the best adult stem cells for cancer on the globe. What was an exquisite and famously powerful, yet gentle VIP cancer-rescue program in collaboration with the Park Hyatt Hamburg SPA Hotel is now turn-key available to the most innovative Arab medical center in 2011.
More than 10,000 liver cancer patients -many from the finest families of Arabia- still die each year in the kingdom of Saudi Arabia, alone; there are more than 200,000 cases in the larger region, if one includes neighboring Egypt. Rather than spending an estimated $5-12billion per year on treatments abroad in the US or EU, the single top Arab CITA-PURGE™ transplant centre that AmeReGen GC Arabia will exclusively enable as licensed JV, top stem cell centre of excellence, and long-term partner for clinical liver cancer care, research, and scientific flagship-program of the world (and ahead of the entire US!) - this centre will be able to save up to 14,000 lives of domestic, expatriate, and regional health tourism a year, and not only likely save 3/4 of the multi- $billion re-current expense to each GC Arabian nation to send their premium liver cancer patients abroad, but create a solid Arab domestic $5-10billion+/year liver cancer health care industry fueled by the critical supply of CITA-PAK therapies. Last not least saving 14,000 lives previously lost to liver cancer will be a priceless Sharia accomplishment and the marvel of the region's medical infrastructure.
Hear AmeReGen GC Arabia CEO Dr. Hope on Price Waterhouse Coopers PwC Entrepreneur Radio - Breakthrough Award 2008 Interview  | WCRadio_AmeReGen.mp3 |
Copyright 2009, 2010 AmeReGen-GC Arabia.SP - all rights reserved.
